Study 0018 (NCT00107978) compares the safety and effectiveness of an investigational drug, telavancin, and an approved drug, vancomycin, for the treatment of complicated skin and skin structure infections.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
1,035
Telavancin 10 mg/kg/day, IV for up to 14 days.
Vancomycin 1 Gm IV administered every 12 hrs for up to 14 days.
Louisiana State University Health Sciences Center, Dept of Med/ER Med
New Orleans, Louisiana, United States
Clinical Response
The Clinical Response for each patient was determined by the investigator by assessing the patient's clinical signs \& symptoms compared with the Baseline evaluation. Cure: resolution of signs and symptoms associated with the skin infection present at study admission such that no further antibiotic therapy was necessary; Not Cured: inadequate response to study therapy; Indeterminate: unable to determine outcome.
Time frame: 7 to 14 days after the last antibiotic dose
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.